DelveInsight's "Hemophilia A Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Hemophilia A Market, historical and forecasted epidemiology, the pipeline insight as well as the Hemophilia A market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Hemophilia A Market Analysis
The Hemophilia A market size is anticipated to increase during the study period owing to the rise in the prevalent population of Hemophilia A, expected entry of premium price assets such as gene therapy, siRNA, and bispecific antibodies, and expected readily uptake of recently approved therapies.
The Hemophilia A market analysis section of the report helps to build a detailed comprehension of the historical, current, and forecasted Hemophilia A market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand for better technology.
The report gives complete detail of Hemophilia A market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Hemophilia A Epidemiology Forecast
The Hemophilia A epidemiology section covers insights about historical and current Hemophilia A patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
It helps to recognize the causes of current and forecasted Hemophilia A Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Some of the key Hemophilia A companies involved in the therapeutics development include:
Sanofi
Pfizer
Roche
Novo Nordisk
Spark Therapeutics
Catalyst Biosciences
Alnylam Pharmaceuticals
Biomarin Pharmaceutical
Sangamo therapeutics
Sigilon Therapeutics
And many others.
Hemophilia A therapies covered in the report include:
Concizumab (NN7415)
Marzeptacog alfa
Fitusiran, BIVV001
RG6357 (SPK-8011)
Marstacimab (PF-06741086)
Valoctocogene Roxaparvovec (BMN 270)
Giroctocogene Fitelparvovec (SB-525 or PF-07055480)
And many more.
For more details, visit: Hemophilia A Market Share and Growth Analysis